Cartesian Therapeutics (RNAC) Operating Expenses (2015 - 2026)

Cartesian Therapeutics (RNAC) has 12 years of Operating Expenses data on file, last reported at $26.6 million in Q1 2026.

• On a quarterly basis, Operating Expenses rose 15.61% year-over-year to $26.6 million in Q1 2026; TTM through Mar 2026 was $149.8 million, a 72.95% increase from a year earlier, with the FY2025 full-year figure at $146.2 million, up 76.55% from the prior year.
• Operating Expenses for Q1 2026 stood at $26.6 million, down from $79.6 million in the prior quarter.
• Over the last five years, Operating Expenses for RNAC reached as high as $79.6 million in Q4 2025 and fell as low as $18.0 million in Q3 2024.
• Historically, Operating Expenses has averaged $27.3 million across 5 years, with a median of $23.2 million in 2022.
• Across the five-year window, Operating Expenses slumped 41.76% in 2024 and soared 206.43% in 2025, its largest moves.
• Year by year, Operating Expenses stood at $25.3 million in 2022, then jumped by 76.34% to $44.6 million in 2023, then slumped by 41.76% to $26.0 million in 2024, then surged by 206.43% to $79.6 million in 2025, then plunged by 66.61% to $26.6 million in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were $26.6 million in Q1 2026, $79.6 million in Q4 2025, and $21.5 million in Q3 2025.